Pseudopelade

SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory (I&I) diseases, today announced it will host a virtual key opinion leader (KOL) event at 10:00 AM ET on Thursday, October 31, 2024. To register, click here. The event will feature Jonathan Silverberg, MD, PhD, MPH (The George Washington University School of Medicine and Health Sciences), Maryanne Senna, MD (Beth Israel Lahey Health, Harvard Medical School), and Yufang Lu, MD, PhD (Inmagene) who will discuss the potential role of anti-OX40/OX40L monoclonal antibodies (mAbs) in the treatment of atopic dermatitis (AD) and alopecia areata (AA). The event will discuss data from emerging OX40/OX40L inhibitors, including Inmagene’s IMG-007 - the only clinical-stage non-depleting anti-OX40 mAb. A live question and answer session will follow the formal presentations. About Jonathan Silverberg, MD, PhD, MPHJonathan Silverberg, MD, PhD, MPH is an Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC. He is the Director of Clinical Research and Contact Dermatitis. Dr. Silverberg completed his undergraduate and medical school training as a part of the highly selective dual B.A./M.D. program at State University of New York Downstate Medical Center, in Brooklyn. Dr. Silverberg also received his doctorate in neuroimmunology and Master of Public Health degree in biostatistics and epidemiology from the State University of New York Downstate Medical Center where he also completed his internship in internal medicine. He completed his residency training in dermatology at St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Centers in New York, NY and served as Chief Resident during his final year. Dr. Silverberg's area of clinical subspecialty is inflammatory skin disease, particularly atopic and contact dermatitis. He has extensive experience in the advanced management of atopic dermatitis, hand eczema, chronic itch, psoriasis, hidradenitis and many other chronic inflammatory skin disorders. He is also a national expert in allergy patch testing, phototesting and photopatch testing. Dr. Silverberg's research interests include drug development, clinical trial design, biomarkers, dermato-epidemiology, health services research, patient-reported outcomes, comorbidities and burden of itch and inflammatory skin disease and evidence-based dermatology. His publications include more than 600 peer-reviewed articles, abstracts and book chapters. He is also the author of the Clinical Management of Atopic Dermatitis handbook (2018). Dr. Silverberg has also been a local, national and/or international principal investigator for numerous clinical trials for novel treatments in atopic dermatitis and other inflammatory disorders. He has been recognized with several honors, including the Young Leadership Award from the American Dermatological Association in 2017, Teacher of the Year Award in the department of dermatology in 2015, Outstanding Teacher's Award from the Feinberg School of Medicine in 2016, 2017 and 2018, and the inaugural Rajka Award from the International Society for Atopic Dermatitis in 2014. He is an associate editor for the Journal of the American Academy of Dermatology, British Journal of Dermatology and Current Dermatology Reports. Dr. Silverberg is a member of the International Eczema Council, North American Contact Dermatitis Group the American Society of Contact Dermatitis. Dr. Silverberg is also the chair of the annual Revolutionizing Atopic Dermatitis global multidisciplinary conference. About Maryanne Senna, MDMaryanne Senna, MD is a board-certified dermatologist at Beth Israel Lahey Health, and assistant professor of dermatology at Harvard Medical School. Dr. Senna founded and directs the Lahey Hair Loss Center of Excellence and serves as principal of the research unit. Prior to this role, she founded the MGH Hair Loss Clinic and clinical trials unit, which she ran for nearly 10 years. She has held a number of pharmaceutical, device, and foundation appointments. Widely published and recognized for her clinical expertise, teaching, and research, Dr. Senna is frequently invited to speak and give lectures nationally and abroad, and has been quoted in top-tier media publications such as The New York Times and The Atlantic. She has also been featured on multiple news outlets including Good Morning America, and in the HBO Max documentary series Not So Pretty. Dr. Senna is an esteemed member of several professional societies and committees, and is on the board of directors of the Scarring Alopecia Foundation, the American Hair Research Society, and on the medical advisory task force for the National Alopecia Areata Foundation. About Yufang Lu, MD, PhDYufang Lu is the Chief Medical Officer of Inmagene. Dr. Lu is an accomplished physician scientist with more than 20 years of experience in clinical development and medical affairs. She has successfully led clinical development for both small molecules and biologics across diverse therapeutic areas, including dermatology, allergy, gastroenterology, and rheumatology. Prior to Inmagene, Dr. Lu was Vice President of Clinical Development at Celldex, where she drove the advancement of innovative immunology assets, including barzovolimab. During her tenure at Regeneron, she led cross-functional medical teams in the global launches of Dupixent® in atopic dermatitis and asthma. Earlier in her career, she held roles in clinical development and medical affairs at Celgene, Eisai, and GSK. Dr. Lu received her medical degree from Nanjing Medical University with residency training in dermatology and a PhD in toxicology from Texas A&M University. About InmageneInmagene is a global clinical-stage biotechnology company developing novel therapeutics for I&I diseases. The company’s highly differentiated clinical-stage pipeline has multiple candidates with best-in-class potential. The lead asset IMG-007, a non-depleting anti-OX40 mAb, is in two global Phase 2a clinical trials in atopic dermatitis and alopecia areata. IMG-004, a non-covalent reversible BTK inhibitor with an extended half-life and pharmacodynamic effect, enabling its potential for once-daily dosing, recently completed the Phase 1 multiple ascending dose (MAD) study and is ready for Phase 2 development. For more information, please visit www.inmagenebio.com. About IMG-007IMG-007 is a humanized anti-OX40 IgG1 mAb, with an extended half-life and silenced antibody-dependent cellular cytotoxicity (ADCC) function. In nonclinical studies, IMG-007 potently blocked the signalling between OX40 and OX40L. IMG-007 is being evaluated for the treatment of moderate-to-severe atopic dermatitis (AD) and severe alopecia areata (AA). In a Phase 2a study in AD patients, a short 4-week treatment with IMG-007 resulted in a rapid and marked improvement in the extent and severity of skin lesions in AD patients. Interim data from a pharmacokinetic study showed that subcutaneous IMG-007 demonstrated an exceptionally long half-life, which would enable its potential for every six months (Q6M) dosing for AD maintenance therapy. Separately, its silenced ADCC function has led to a favorable safety profile, without any reports of pyrexia and chills, differentiating it from a competing ADCC-enhanced anti-OX40 mAb. Inmagene has in-licensed IMG-007’s exclusive global rights from HUTCHMED. Forward-Looking StatementsThis press release contains forward-looking statements. While Inmagene believes the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For further information, please contact:Inmagene:Anna Vardanyan, MD, PhDSVP of Corporate and Business Developmentvardanyana@inmagenebio.com Investor Relations:Bruce MackleLifeSci Advisors, LLCbmackle@lifesciadvisors.com

In the bright river of stars in the field of medicine, a new star is rising slowly, which has lit up the light of hope for countless patients with alopecia areata. Recently, Sun Pharma announced that its innovative drug Leqselvi (deuruxolitinib) was successfully approved by the US Food and Drug Administration (FDA), officially entering the battlefield of treating severe alopecia areata in adults. This milestone achievement not only marks a new era of precise targeting of cytokines in the treatment of alopecia areata, but also brings unprecedented treatment hope to the 147 million patients worldwide who are affected by alopecia areata. Alopecia areata, behind this seemingly simple word, actually hides the bitterness and helplessness of countless patients. As a common inflammatory non-scarring alopecia, alopecia areata (AA) not only seriously affects the appearance of patients with its unique symptoms of 'scratching the head', but also virtually erods their mental health and quality of life. In China, about 4 million people are suffering from the pain and inconvenience caused by alopecia areata, and they yearn to regain their hair, confidence and dignity. In retrospect, the treatment of AA has been full of bumps and challenges. For a long time, glucocorticoids, as the main treatment for alopecia areata, can relieve the disease to a certain extent, but the adverse reactions caused by its long-term use have discouraged patients. Uncertainty about efficacy, recurrent nightmares, and, in severe cases, the absence of hair growth on the entire scalp or even the whole body, have driven patients with alopecia areata into deep despair. However, scientific progress never stops. With the deepening of the research on the pathogenesis of alopecia areata, scientists have gradually unveiled the mystery of this stubborn disease. Studies have found that key pathogenic factors such as IFN-γ and IL-15 play an important role in the pathogenesis of alopecia areata. They activate the JAK-STAT pathway, which triggers a series of immune responses, leading to hair follicle damage and hair loss. This major discovery provides a new idea for the treatment of alopecia areata by blocking the effect of pathogenic factors by inhibiting JAK signaling pathway, so as to achieve precision treatment. In this context, JAK inhibitors emerged and quickly became the new darling in the field of AA treatment. At present, three JAK inhibitors have been successfully approved for the indication of AA worldwide, providing more treatment options for patients with AA. Leqselvi from Sun Pharmaceutical stands out with its excellent efficacy and safety, and has become a bright pearl in the field of alopecia areata treatment. The approval of Leqselvi not only means that patients with alopecia areata will usher in more accurate and effective treatment methods, but also heralds the arrival of a new era of alopecia areata treatment. By precisely targeting the JAK-STAT pathway that key pathogenic factors such as IFN-γ and IL-15 depend on, this innovative drug effectively blocks the progression of the disease and brings significant therapeutic effects to patients. Clinical trial data show that Leqselvi has shown encouraging efficacy and safety in the treatment of severe alopecia areata, bringing hope to many patients for hair regrowth. With the extensive application and in-depth study of JAK inhibitors such as Leqselvi, we have reason to believe that the persistent disease of alopecia areata will no longer be an invincible enemy. A new, targeted treatment is sure to help restore confidence and dignity to the 147 million people with hair loss. Let's look forward to this day.

LOS ANGELES, Sept. 5, 2023 /PRNewswire/ -- Researchers at Dr. U Hair and Skin Clinic in Los Angeles uncover a crucial link between two medically challenging conditions - Acne Keloidalis Nuchae and Primary Cicatricial Alopecias often called scarring alopecias. Published in the Clinical Cosmetic and Investigational Dermatology journal under "Unveiling a Common Precursor Condition for Acne Keloidalis Nuchae and Primary Cicatricial Alopecias," the findings have significant implications for diagnostics and treatments. Continue Reading PIILIF is a root condition that potentially links all common scarring alopecias Tweet this Researchers link all common scarring alopecias to a single root condition called PIILIF (perifollicular infundibulo-isthmic lymphocytic infiltrates and fibrosis) Acne Keloidalis Nuchae (AKN) is one of a group of scalp conditions called scarring alopecias, known for chronic inflammation causing scarring hair loss with pain, discharge, itching, and social debilitation. AKN often results in disfiguring keloid-like lesions. The research investigated hidden links and shared root conditions. Traditionally, AKN and scarring alopecias were studied in isolation. This research reveals a link called "Perifollicular Infundibulo-Isthmic Lymphocytic Infiltrates Fibrosis" (PIILIF), identified in the normal-appearing scalp (NAS) zones of all AKN patients. PIILIF could shed light on early AKN and scarring alopecia stages. Dr. Sanusi Umar, the study's lead researcher, also head of the scalp and hair disorder section at Harbor-UCLA's dermatology division, underscores that this discovery suggests the potential for more precise therapies targeting root causes and refining diagnostic strategies. Dr. Umar explained, "Our findings, along with other studies, suggest that PIILIF potentially links all common scarring alopecias, such as AKN, folliculitis decalvas (FD), lichen planopilaris (LPP), frontal fibrosing alopecia, and central centrifugal cicatricial alopecia. This highlights their interconnections, offering new insights into their origins and enabling a more holistic diagnostic and therapeutic strategy. Moreover, this might streamline the intricate classification of scarring alopecias by reducing redundancies in closely related conditions. For instance, our research questions the necessity of the entity currently designated LPP-FD phenotype." Surprisingly, the study found AKN to be more prevalent than previously realized in European-descended White males (10% of patients), often unnoticed or misdiagnosed as nape irritation or dandruff. This finding challenges AKN's perception as solely affecting people of color. The study has significant implications, potentially reshaping our understanding of AKN, scarring alopecia, and treatments. Further research is needed to uncover PIILIF's mechanisms, triggers, and role in hair loss. Nonetheless, this work paves the way for improved diagnosis, treatment, and patient well-being. For media inquiries, please contact: Sara Harutyunyan Dr. U Hair and Skin Clinic sara@dru.com SOURCE Dr. U Hair and Skin Clinic